Commentary

Video

Dr Levy on the Potential for ADCs in NSCLC

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Benjamin Levy, MD, clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, discusses antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC) management.

ADCs have emerged as a focal point of clinical interest in NSCLC, Levy explains. Delving into persisting inquiries surrounding the efficacy of ADCs, Levy provides detailed insights into the patient and disease characteristics that may warrant consideration for the use of ADCs and emphasizes the ongoing and prospective research endeavors within the NSCLC treatment domain.

In August 2022, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with unresectable or metastatic NSCLC harboring activating HER2 mutations after prior systemic therapy. Given the diverse landscape of HER2 alterations, including overexpression, amplification, and mutations, precise molecular profiling is essential to determine patient eligibility, since the indication only covers patients with NSCLC harboring HER2 mutations, Levy says.

Although trastuzumab deruxtecan is currently indicated for use in this patient population after chemotherapy, ongoing investigations could help determine the optimal positioning of the ADC within the treatment continuum, including as a potential first-line option. Additionally, Levy notes that investigating the feasibility of combining ADCs with established modalities such as immunotherapy and platinum-based chemotherapy is warranted to comprehensively delineate safety and efficacy profiles.

Levy notes that the trajectory of ADCs in NSCLC represents an unfolding narrative, with important, new chapters awaiting elucidation. Clinical trials exploring the utility of ADCs across diverse clinical settings, including neoadjuvant and adjuvant contexts, hold promise in revealing their complete therapeutic potential. Particularly, evaluating the synergy between ADCs and immunotherapy stands as a focal point with potential implications for treatment outcomes, Levy concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity